Koshinski Asset Management
IMMX icon

Koshinski Asset Management’s Immix Biopharma IMMX Stock Holding History

Koshinski Asset Management’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-51,001
Closed -$174K – 566
2023
Q3 		$174K Hold
51,001
– – 0.02% 539
2023
Q2 		$137K Buy
+51,001
New +$107K 0.01% 580

Other funds holding IMMX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $1.12B AUM 390.6% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
IW
Imprint Wealth Mount Pleasant, South Carolina $24.6M AUM 43.43% 1-Year Est. Return
MAWA
Moss Adams Wealth Advisors Seattle, Washington $1.6B AUM 28.24% 1-Year Est. Return

Koshinski Asset Management's IMMX Position: Q4 2023 in Review

Koshinski Asset Management sold out of Immix Biopharma (IMMX) in Q4 2023, closing a stake of 51,001 shares — an estimated $174K sold.

Koshinski Asset Management first reported a position in IMMX in Q2 2023 and held it in 2 quarters. The position peaked at $174K in Q3 2023. 28 funds tracked by Wall St. Rank hold IMMX as of Q4 2023.

  • Koshinski Asset Management reported no remaining Immix Biopharma position as of Q4 2023 after selling out during the quarter.
  • Koshinski Asset Management sold 51,001 Immix Biopharma shares in Q4 2023, an estimated $174K.
  • Koshinski Asset Management first reported a position in Immix Biopharma in Q2 2023 and held it in 2 quarters.
  • Koshinski Asset Management's Immix Biopharma position peaked at $174K in Q3 2023.
  • 28 funds tracked by Wall St. Rank held Immix Biopharma as of Q4 2023.

Based on Koshinski Asset Management's 13F filing for Q4 2023, filed 29 Jan 2024.